Many clinical trials have established the effectiveness of endocrine therapy (ET), human epidermal growth receptor 2 (HER2) targeted therapy, and bone modifying agents (bisphosphonates and denosumab) in preventing BC progression [4–7]. Here, ERBB2 is linked to breast cancer.